181 related articles for article (PubMed ID: 29336259)
1. p53 as the Focus of Gene Therapy: Past, Present and Future.
Valente JFA; Queiroz JA; Sousa F
Curr Drug Targets; 2018; 19(15):1801-1817. PubMed ID: 29336259
[TBL] [Abstract][Full Text] [Related]
2. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
3. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
4. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
5. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.
Harris CC
J Natl Cancer Inst; 1996 Oct; 88(20):1442-55. PubMed ID: 8841019
[TBL] [Abstract][Full Text] [Related]
6. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.
Zhang WW; Li L; Li D; Liu J; Li X; Li W; Xu X; Zhang MJ; Chandler LA; Lin H; Hu A; Xu W; Lam DM
Hum Gene Ther; 2018 Feb; 29(2):160-179. PubMed ID: 29338444
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of the p53 tumor suppressor gene.
Beaudry GA; Bertelsen AH; Sherman MI
Curr Opin Biotechnol; 1996 Dec; 7(6):592-600. PubMed ID: 8939636
[TBL] [Abstract][Full Text] [Related]
8. Viral-mediated gene transfer for cancer treatment.
Wilson DR
Curr Pharm Biotechnol; 2002 Jun; 3(2):151-64. PubMed ID: 12022258
[TBL] [Abstract][Full Text] [Related]
9. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.
Blumenthal RD; Leone E; Goldenberg DM; Rodriguez M; Modrak D
Int J Cancer; 2004 Jan; 108(2):293-300. PubMed ID: 14639618
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-tumor effects of nitroreductase mutants and p53.
Razmkhah M; Habibagahi M; Alizadeh F; Hosseini A; Ghaderi A; Searle PF; Jaberipour M
J Cancer Res Ther; 2014; 10(3):665-70. PubMed ID: 25313757
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
[TBL] [Abstract][Full Text] [Related]
13. Combined radiation and p53 gene therapy of malignant glioma cells.
Badie B; Goh CS; Klaver J; Herweijer H; Boothman DA
Cancer Gene Ther; 1999; 6(2):155-62. PubMed ID: 10195882
[TBL] [Abstract][Full Text] [Related]
14. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.
Farnebo M; Bykov VJ; Wiman KG
Biochem Biophys Res Commun; 2010 May; 396(1):85-9. PubMed ID: 20494116
[TBL] [Abstract][Full Text] [Related]
15. p53 Replacement Therapy for Cancer.
Tazawa H; Kagawa S; Fujiwara T
Recent Results Cancer Res; 2016; 209():1-15. PubMed ID: 28101684
[TBL] [Abstract][Full Text] [Related]
16. p53-targeted cancer pharmacotherapy: move towards small molecule compounds.
Kim SH; Dass CR
J Pharm Pharmacol; 2011 May; 63(5):603-10. PubMed ID: 21492161
[TBL] [Abstract][Full Text] [Related]
17. p53 tumor suppressor gene therapy for cancer.
Roth JA; Swisher SG; Meyn RE
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):148-54. PubMed ID: 10550840
[TBL] [Abstract][Full Text] [Related]
18. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
19. Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.
Miettinen S; Ylikomi T
Anticancer Drugs; 2009 Aug; 20(7):589-600. PubMed ID: 19491654
[TBL] [Abstract][Full Text] [Related]
20. Establishment of ponasterone A-inducible the wild-type p53 protein-expressing clones from HSC-1 cells, cell growth suppression by p53 expression and the suppression mechanism.
Hori M; Suzuki K; Udono MU; Yamauchi M; Mine M; Watanabe M; Kondo S; Hozumi Y
Arch Dermatol Res; 2009 Oct; 301(9):631-46. PubMed ID: 19009304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
